Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort

Response to antiretroviral therapy (ART) among individuals infected with HIV‐2 is poorly described. We compared the immunological response among patients treated with three nucleoside reverse‐transcriptase inhibitors (NRTIs) to boosted protease inhibitor (PI) and unboosted PI‐based regimens in West Africa.

[1]  P. Morlat,et al.  [Reproductive options for people living with HIV: 2013 guidelines from the French expert working group]. , 2014, Gynecologie, obstetrique & fertilite.

[2]  C. Charpentier,et al.  Genotypic resistance profiles of HIV-2-treated patients in West Africa , 2014, AIDS.

[3]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[4]  G. Gottlieb,et al.  Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study , 2013, PloS one.

[5]  G. Gottlieb,et al.  Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line Therapy , 2013, Antimicrobial Agents and Chemotherapy.

[6]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[7]  R. Camacho.  Special Aspects of the Treatment of HIV-2-Infected Patients , 2012, Intervirology.

[8]  B. Chi,et al.  Universal Definition of Loss to Follow-Up in HIV Treatment Programs: A Statistical Analysis of 111 Facilities in Africa, Asia, and Latin America , 2011, PLoS medicine.

[9]  F. Brun-Vézinet,et al.  Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Gandhi,et al.  Update on human immunodeficiency virus (HIV)-2 infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Rowland-Jones,et al.  Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings , 2011, AIDS research and treatment.

[12]  M. Egger,et al.  Correcting Mortality for Loss to Follow-Up: A Nomogram Applied to Antiretroviral Treatment Programmes in Sub-Saharan Africa , 2011, PLoS medicine.

[13]  A. Meliço-Silvestre,et al.  Treatment of HIV-2 infection: a retrospective study from a Portuguese center , 2010, Journal of the International AIDS Society.

[14]  F. Dabis,et al.  First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration , 2010, AIDS.

[15]  A. Harries,et al.  Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. , 2010, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[16]  L Harrison,et al.  Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data , 2009, Statistics in medicine.

[17]  F. Sarfo,et al.  Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study. , 2009, The Journal of antimicrobial chemotherapy.

[18]  F. Brun-Vézinet,et al.  Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients , 2009, AIDS.

[19]  S. Rowland-Jones,et al.  Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant Variants , 2009, Journal of Clinical Microbiology.

[20]  R. van Crevel,et al.  Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. , 2009, AIDS.

[21]  F. Antunes,et al.  20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  G. Gottlieb,et al.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  G. Gottlieb,et al.  A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. , 2008, AIDS.

[24]  S. Matheron.  HIV-2 infection: a call for controlled trials , 2008 .

[25]  Jeffrey N. Martin,et al.  Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. , 2008, JAMA.

[26]  A. Rodrigues,et al.  Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? , 2008, AIDS.

[27]  E. Freire,et al.  Inhibition of HIV‐2 Protease by HIV‐1 Protease Inhibitors in Clinical Use , 2008, Chemical biology & drug design.

[28]  F. Brun-Vézinet,et al.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France , 2008, AIDS.

[29]  F. Brun-Vézinet,et al.  In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[30]  S. Eholie,et al.  Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? , 2006, International journal of epidemiology.

[31]  H. Whittle,et al.  Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. , 2006, International journal of epidemiology.

[32]  S. Rowland-Jones,et al.  Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia , 2006, AIDS.

[33]  F. Brun-Vézinet,et al.  CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort , 2006, AIDS.

[34]  S. Popper,et al.  Highly active antiretroviral therapy and viral response in HIV type 2 infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  W. Heneine,et al.  Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis , 2004, Antiviral therapy.

[36]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[37]  A. Osterhaus,et al.  Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV‐2‐infected patients , 2003, AIDS.

[38]  W. Heneine,et al.  Antiretroviral therapy in HIV‐2‐infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire , 2003, AIDS.

[39]  D. Stuart,et al.  Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Egger,et al.  Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. , 1999, AIDS.

[41]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[42]  Gerald Gartlehner,et al.  [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.